Nanoparticle Chemotherapy for Breast Cancer

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen by Mina Sedrak, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: City of Hope Medical Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

RATIONALE: Gathering information from patients of different ages receiving paclitaxel albumin-stabilized nanoparticle formulation for metastatic breast cancer may help doctors understand how the age of the patient changes the way the drug works. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients of different ages with metastatic breast cancer.

Research Team

Mina Sedrak, MD

Principal Investigator

City of Hope Medical Center

Eligibility Criteria

This trial is for individuals with metastatic breast cancer, regardless of hormone receptor status, who are planning to receive their first or second round of chemotherapy. It's not suitable for those with untreated brain metastases or symptoms needing increasing steroid doses.

Inclusion Criteria

My breast cancer has spread to other parts of my body.

My breast cancer can be any type, but I will be treated with a specific chemotherapy drug.

I am planning to start my first or second chemotherapy for advanced cancer.

Exclusion Criteria

I have brain metastases that haven't been treated or need more steroids to manage symptoms.

Treatment Details

Interventions

• Paclitaxel Albumin-Stabilized Nanoparticle Formulation (Anti-microtubule agent)

Trial Overview The study focuses on how well a drug called paclitaxel albumin-stabilized nanoparticle formulation works in treating different age groups with advanced breast cancer. It includes cognitive and psychosocial assessments, pharmacological studies, and questionnaires.

Participant Groups

Group I: nab-paclitaxel Experimental Treatment 7 Interventions

Who Is Running the Clinical Trial?

City of Hope Medical Center

Lead Sponsor

Trials

614

Recruited

1,924,000+

Robert Stone

City of Hope Medical Center

Chief Executive Officer since 2014

Juris Doctorate from the University of Chicago, Bachelor's degree in Political Science from the University of Redlands

Sumanta (Monty) Pal

City of Hope Medical Center

Chief Medical Officer since 2023

MD

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School